Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences to Present at Upcoming Investor Conferences
Live webcasts of these presentations can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: . A replay of these presentations will be archived and available on the site for a limited time following the event.CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December.
美国马萨诸塞州剑桥，2024年11月26日（全球新闻通讯） -- wave life sciences有限公司（纳斯达克：WVE），是一家专注于发掘RNA药物广泛潜力以改变盈健医疗的临床阶段生物技术公司，今日宣布，首席执行官兼总裁Paul Bolno，医学博士，MBA，计划参加12月的两场投资者会议。
7th Annual Evercore HealthCONx Conference
Date: Tuesday, December 3, 2024
Analyst-led fireside chat: 3:00 p.m. ET
第七届evercore HealthCONx大会
日期：2024年12月3日星期二
分析师主导的炉边聊天：东部时间下午3:00
Citi 2024 Global Healthcare Conference
Date: Wednesday, December 4, 2024
"Neuromuscular Disorders" panel: 1:00 p.m. ET
Citi 2024全球医疗会议
日期：2024年12月4日星期三
"神经肌肉疾病"会议：东部时间下午1:00
Live webcasts of these presentations can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: . A replay of these presentations will be archived and available on the site for a limited time following the event.
通过访问Wave Life Sciences网站投资者关系部分的"投资者活动"可以访问这些演示的直播网络会议。事件后，这些演示的重播将被存档，并在网站上有限时间内提供。
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington's disease, as well as a preclinical program in obesity. Driven by the calling to "Reimagine Possible", Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn.
关于Wave Life Sciences
Wave Life Sciences（纳斯达克：WVE）是一家生物技术公司，专注于发掘RNA药物的广泛潜力，以改变盈健医疗。Wave的RNA药物平台PRISm结合了多种应用、化学创新和对人类遗传学的深入洞察，提供科学突破，以治疗稀有和普遍疾病。其RNA靶向工具包包括编辑、剪接、RNA干扰和反义沉默，赋予Wave设计和可持续交付候选药物的无与伦比的能力，能够最佳解决疾病生物学。Wave多元化的开发管线包括杜氏肌营养不良症、α-1抗胰蛋白酶缺乏症和亨廷顿病的临床项目，以及一个针对肥胖的临床前项目。受到“重新想象可能”的召唤，Wave正在引领迈向一个人类潜能不再因疾病负担而受阻的世界。Wave总部位于马萨诸塞州剑桥。有关Wave的科学、管线和团队的更多信息，请访问并在X（前身为Twitter）和LinkedIn上关注Wave。
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
投资者联系人：
凯特·劳斯
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
媒体联系：
艾丽西亚·苏特
+1 617-949-4817
asuter@wavelifesci.com
